Immunomodulative effect of glucan and/or glucan supplemented with zinc in albendazole therapy for murine alveolar echinococcosis.
The effect of glucan immunomodulator (GI) and glucan supplemented with zinc (GIZn) administered separately or with albendazole (ABZ) on cellular immunity of mice with alveolar echinococcosis was observed. The stimulative effect of GI and GI + ABZ therapy on proliferative response of T lymphocytes was prolonged by GIZn or GIZn + ABZ from week 6 to 14 postinfection (p.i.). The increased proliferation of B lymphocytes was observed during combined therapies GI + ABZ and GIZn + ABZ from week 6 to 12 p.i. Number of splenic CD4 T cells in mice with GI or GI + ABZ therapy was increased only on weeks 6 and 8 p.i. GIZn and GIZn + ABZ therapy prolonged this stimulation from week 6 to 14 p.i. Serum concentration of interferon-gamma (IFN-gamma) was increased after GIZn therapy and reduced after GI therapy from week 8 to 12 p.i. GIZn + ABZ therapy had the highest effect on the IFN-gamma rise from week 8 to 22 p.i. Both GI and GIZn inhibited the serum concentration of interleukin-5 (IL-5) from week 6 p.i. The production of superoxide anion was increased after GI therapy from week 6 to 14 p.i. and after GI + ABZ or GIZn + ABZ therapies from week 12 to 18 p.i. The most effective antiparasitic therapy for alveolar echinococcosis was reached by GIZn + ABZ therapy.
Porubcová
Jarmila
J
Parasitological Institute of the Slovak Academy of Sciences, Hlinkova 3, 040 01 Kosice, Slovak Republic.
Dvoroznáková
Emília
E
Sevcíková
Zuzana
Z
D015766:Albendazole / Q000008:administration & dosage*; D000818:Animals; D000977:Antiparasitic Agents / Q000008:administration & dosage / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D019587:Dietary Supplements; D004359:Drug Therapy, Combination; D004445:Echinococcosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology*; D008297:Male; D051379:Mice; D011509:Proteoglycans; D011650:Pulmonary Alveoli; D013047:Specific Pathogen-Free Organisms; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D015032:Zinc / Q000008:administration & dosage / Q000276:immunology; D047071:beta-Glucans / Q000008:administration & dosage / Q000276:immunology
D000977:Antiparasitic Agents; D011509:Proteoglycans; D047071:beta-Glucans; C010770:polysaccharide-K; D015766:Albendazole; D015032:Zinc